|
|
Upfront Briefing
Telix is buying ITM for $1.65B upfront, almost all of it in stock, with up to $700M more riding on an ITM-11 approval that an August CRL put on hold. The real prize is ITM’s lutetium-177 business. Xenon got its epilepsy NDA in the door and lost 23% in the same breath, pausing psychiatry trials after psychosis events — the second Kv7 opener to stumble this month. Beacon posted the first pivotal win in XLRP, and IMS opens Wednesday in Glasgow for the myeloma crowd.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,650.5 |
0.2% |
11.8% |
| Nasdaq 100 |
29,644.2 |
0.7% |
17.6% |
| Russell 2000 |
2,860.4 |
(0.5%) |
15.2% |
| Healthcare (XLV) |
168.4 |
(0.2%) |
8.8% |
| Biotech (XBI) |
156.7 |
(1.0%) |
28.5% |
| Nasdaq Biotech (NBI) |
6,970.5 |
(1.3%) |
22.1% |
| Clinical Trials (BBC) |
48.6 |
(1.3%) |
29.2% |
|
- Biotech gave back part of Thursday’s beta rally: XBI (1.0%), NBI (1.3%) and BBC (1.3%) against XLV (0.2%) and an S&P 500 up 0.2%. The heaviest single-name hit was Xenon, about 23% lower premarket after pausing its psychiatry trials on Thursday evening.
- Chips carried the Nasdaq 100 up 0.7% — Broadcom +3%, Micron +3.9% — while the Dow slipped 0.2% and the Russell 2000 lost 0.5%. The 10-year climbed back to about 5.00% on Middle East oil-supply uncertainty, pressuring banks, on a quarterly triple-witching expiry two days after the Fed’s 25bp hike.
- Market data: U.S. cash close Friday, 18 September 2026.
The Big 3
|
1
|
Telix buys ITM for $1.65B upfront to lock in Lu-177
|
- Telix will acquire all of privately held ITM Isotope Technologies Munich for $1.65B upfront on a cash-free/debt-free basis: 105.8M Telix shares worth about $1.25B at a $11.84 trailing VWAP, $302M of assumed net debt and roughly $96M of management rollover and expenses. Up to $700M more is tied to ITM-11 (177Lu-edotreotide): $250M across three FDA approvals and $450M on FY2030 sales above $150M. ITM holders take 23.7%; Telix votes in November, closing by year-end.
- Why it matters: This is a supply deal wearing a pipeline deal’s clothes. ITM booked $273M of 2025 revenue, mostly lutetium-177, and two of Telix’s three pivotal-stage therapeutics are Lu-177 constructs, so owning the only globally scaled commercial producer takes a critical input off someone else’s allocation list. The contingent $700M is where the risk sits. ITM-11 won Phase 3 COMPETE, but Telix says the August CRL cited manufacturing controls and third-party facilities, not clinical data, making the first $100M a CMC-fix bet with a 2027 deadline. An approval would land in a GEP-NET market that added Curium’s Bexlutry last week, against Novartis’ Lutathera. Paying in stock also hands ITM’s backers 23.7% of Telix under lockups of up to 15 months: that is the overhang to watch.
- Source: STAT
- More: PR
|
|
2
|
Xenon drops 23% as azetukalner psychiatry trials pause
|
- Xenon paused new enrolment in its Phase 3 major depressive disorder and bipolar depression studies of azetukalner after psychosis-coded neuropsychiatric events, mostly mild to moderate, and disclosed on the same Thursday-evening call that its NDA in focal onset seizures is with the FDA. X-NOVA2 in MDD closes at 360 of a planned 450 patients, with topline now Q1 2027. Shares fell to $44.27 premarket Friday from $57.35.
- Why it matters: The market marked down the epilepsy franchise, not just the depression option. The FOS filing rests on X-TOLE2’s 42.7% placebo-adjusted cut in seizure frequency and a $2B-plus sales case at Jefferies, with a decision around September 2027. But psychosis cases already appeared in X-TOLE, X-TOLE2 and a healthy-volunteer study, so reviewers now have a pattern to probe and a label-language risk that no efficacy number offsets. This is also the second Kv7 opener to stumble this month: Biohaven’s opakalim took an FDA partial hold over a rodent metabolite two weeks after SK Biopharmaceuticals agreed to license it for up to $795M. Xenon says the issues are unrelated. Its proposed fix is dose titration, which gives up the no-titration convenience William Blair calls a key selling point.
- Source: Fierce Biotech
- More: BioSpace
|
| 3 | Beacon’s laru-zova posts XLRP’s first pivotal win |
- Beacon’s VISTA trial of laru-zova (n=85) met its FDA-endorsed primary endpoint: 31.0% of the high-dose group (p=0.0019) and 24.1% of the low-dose group (p=0.0106) gained at least 15 letters of low-luminance visual acuity at 12 months, against no responders among untreated controls. A rolling BLA starts later this year, with full data at AAO on 10 October.
- Why it matters: The dose response runs the wrong way on the secondaries, and that is the question for October. Low dose beat high dose on 10-letter responders, 58.6% to 48.3%, and was the only arm to clear microperimetry, where high dose missed at p=0.0614. That does not threaten a filing built on the primary, but it will shape which dose reaches a label. The competitive read is cleaner: prior pivotal attempts in XLRP, including J&J and MeiraGTx’s bota-vec, missed, so Beacon holds the only positive registrational dataset in a disease hitting roughly 1 in 25,000 males. Beacon is private; the listed handle is Syncona, which owns 38.4% and carried the stake at £183.4M at 30 June, a mark this readout should move.
- Source: Fierce Biotech
- More: PR
|
Everything Else that broke
- Lilly won FDA approval for Inluriyo (imlunestrant) plus Verzenio in second-line HR+/HER2- advanced breast cancer, four days after AstraZeneca’s oral SERD Etcamah missed first-line. — Fierce Pharma
- EMA’s CHMP backed a slate of new medicines at its September meeting, including a haemophilia A prophylaxis from Novo and new AstraZeneca products. — Fierce Pharma
- All 50 states, DC and Puerto Rico signed up to the Medicaid MFN ‘GENEROUS’ model; the White House puts decade savings at $27.6B for states and $36.6B federally. — Endpoints
- China’s new five-year biotech plan targets five global blockbusters and a $522B sector by 2030. — Endpoints
- FDA data show first-cycle rejection rates for new drugs fell from 47% in 2008 to about 27% in 2024, pushing back on the tougher-agency narrative. — Endpoints
- IMS opens Wednesday in Glasgow (23–26 Sep); BCMA and GPRC5D bispecifics and CAR-T at first relapse are the focus, with BMS’s pivotal arlo-cel win awaiting full data. — BioSpace
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Telix / ITM Isotope Technologies Munich — $1.65B upfront, cash-free/debt-free, ~$1.25B in Telix stock plus $302M assumed net debt; up to $700M contingent on ITM-11 (see The Big 3). — STAT
- Novo / Kallyope — three early-stage obesity programs; terms undisclosed. — Fierce Biotech
VC / Private Financings
- No notable VC or private financings since Friday.
IPOs / Follow-Ons
- No notable IPOs or follow-ons since Friday.
Academic Corner - NEJM argued gene therapy for sickle cell disease remains out of reach for most patients bearing the global burden. — NEJM
- Lancet correspondence discussed lessons from KEYNOTE-B96 in platinum-resistant ovarian cancer. — Lancet
|
One merger, one Kv7 wobble, one first-ever. Back tomorrow.
— BioBucks Team
|
|
|
